ASX:BB1 ASX Announcement 11 November 2026 BlinkLab Reports Positive Results in Genetic Autism Study, Ahead of Schedule Highlights ? Strong multi-domain biomarker signal in SHANK2-related autism: Individuals with a SHANK2 mutation (n = 8) showed significant differences in BlinkLab smartphone-tests...
Positive Results in Genetic Autism Study Ahead of Schedule
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The study utilized smartphone-based assessments to measure neurophysiological differences, supporting the biological relevance of BlinkLab's technology in diagnosing neurodevelopmental disorders. These findings open potential avenues for therapeutic development and underscore the importance of objective measures in clinical trials for autism.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from BlinkLab
- Trading Halt
- Quarterly Activities/Appendix 4C Cash Flow Report
- Commencement of Nationwide Autism Screening in Morocco
- BB1 to Present at Simons Foundation and ThinkEquity in NYC
- BB1 to Present at Spark Plus Aussie Equities Day Singapore
Follow BlinkLab into a list and get an email when it puts out news.
Follow BlinkLab